RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takesI am not sure you and others are reading my posts correctly as I do not get why you think what your are saying about my position. Maybe some are suffering PTSD from my voting for management last year and assume I will do so again this year. That decision did turn out to be a bad one given the ultimate outcome of the highly dilutive share offering to IQ which I believe was inlarge measure meant to protect THTX's top leader's jobs. That will likely prove to be asuccessful exercise as it seems unlikely the votes will be there for any of the board members to be voted out this year. Due largely to bad financing deals like the IQ one, THTX has already functionally gone bankrupt, even if it has not technially done so, as it has lost 97% of its value from the peak share price nearly six years ago even as the sales from the company's two approved drugs have improved over that time frame. There is still a chance the Sort1+ platform amounts to something that helps partially rescue the company from its current malaise but clearly, good or great results need to be seen in the current trial if that is going to happen. THTX stock price should also recover significantly from its current functionally bankrupt level if they can avoid breaking any additional Marathon covenants and pay down that debt while keeping Egrifta and Trogarzo sales moving higher. As a result, it is likley smart to continue holding the stock despite what its leadership has done to harm shareholders via their various financing deals. I think spending money on cancer was a wise move since the preclinical work was so positive, so I don't think that was a foolhardy decision, but I have to think a significant amount of the dilution the company has caused via financing that spending could have been avoided in a variety of ways.
I have not made up my mind yet how I will vote but you can easily imagine which way I am leaning even though voting against board members is something I do not like to ever do. And as I said, my votes and those of others on this message board are not likely to be able to bring about change anyway this year as the IQ and other institutional investors will likely vote for the current board, which should be enough for them to keep their jobs. But every shareholder should vote as they deem appropriate even if the outcome already seems known.